Results 31 to 40 of about 4,640 (210)

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design

Future Oncology
Selinexor is an investigational, selective oral XPO1 inhibitor that may inhibit myelofibrosis (MF)-relevant JAK/STAT and non-JAK/STAT pathways with potential synergy with ruxolitinib.
J. Mascarenhas, Keri Maher, R. Rampal, P. Bose, Nikolai Podoltsev, Junshik Hong, Yi Chai, Steve Kye, M. Method, C. Harrison   +9 more
semanticscholar   +1 more source

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma

Experimental Hematology & Oncology, 2023
Leiomyosarcoma (LMS) is a rare soft tissue sarcoma (STS) that begins in smooth muscle tissue and most often initiates in the abdomen or uterus. Compared with other uterine cancers, uterine LMS (ULMS) is an aggressive tumor with poor prognosis and a high ...
Sonam Mittal, Ishaque Pulikkal Kadamberi, Hua Chang, Feng Wang, Sudhir Kumar, Shirng-Wern Tsaih, Christopher J. Walker, Pradeep Chaluvally-Raghavan, John Charlson, Yosef Landesman, Sunila Pradeep   +10 more
doaj   +1 more source

Selinexor and COVID-19: The Neglected Warden

Frontiers in Pharmacology, 2022
A novel severe acute respiratory distress syndrome coronavirus type 2 (SARS-CoV-2) has been confirmed as the cause of the global pandemic coronavirus disease 2019 (COVID-19). Different repurposed drugs have been trialed and used in the management of COVID-19. One of these agents was the anti-cancer Selinexor (SXR).
Gomaa Mostafa-Hedeab, Gomaa Mostafa-Hedeab, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nermeen N. Welson, Gaber El-Saber Batiha, Carlos Adam Conte-Junior   +6 more
openaire   +3 more sources

LONG-TERM FOLLOW-UP OF EFFICACY AND SAFETY OF SELINEXOR MAINTENANCE TREATMENT IN PATIENTS WITH TP53WT ADVANCED OR RECURRENT ENDOMETRIAL CANCER: A SUBGROUP ANALYSIS OF THE ENGOT-EN5/GOG-3055/SIENDO STUDY

Gynecologic Oncology
Objective: To report initial long-term efficacy and safety of selinexor maintenance therapy in adults with TP53 wild-type (TP53wt) stage IV or recurrent endometrial cancer (EC) who achieved partial remission (PR) or complete remission (CR) following ...
V. Makker, J. Pérez-Fidalgo, G. Valabrega, Erika Hamilton, T. van Gorp, J. Sehouli, K. Regináčová, Debra L. Richardson, Tamar Perri, A. Oza, D. Miller, E. G. Alía, U. de Giorgi, S. Henry, D. Spitz, P. Wimberger, M. Bednaříková, H. Chon, J. Martínez-Garcia, C. Pisano, J. Berek, Ignacio Romero, G. Scambia, L. Fariñas-Madrid, J. Buscema, F. Schochter, Kai Li, Pratheek Kalyanapu, C. Walker, I. Vergote   +29 more
semanticscholar   +1 more source

XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Journal of Hematology & Oncology, 2020
The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies ...
Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W. L. Choi, Jooryung Huh, Maurilio Ponzoni, Andrés J. M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Fredrick Hagemeister, Lapo Alinari, Yong Li, Michael Andreeff, Bing Xu, Ken H. Young   +28 more
doaj   +1 more source

Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

Journal of Experimental & Clinical Cancer Research, 2021
Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53.
Valentina Zuco, Sandro Pasquali, Monica Tortoreto, Silvia Brich, Stefano Percio, Gian Paolo Dagrada, Chiara Colombo, Roberta Sanfilippo, Calogero Lauricella, Mrinal Gounder, Rihan El Bezawy, Marta Barisella, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti, Nadia Zaffaroni   +16 more
doaj   +1 more source

Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor

Journal of Translational Medicine
Targeting exportin1 (XPO1) with Selinexor (SEL) is a promising therapeutic strategy for patients with multiple myeloma (MM). However, intrinsic and acquired drug resistance constitute great challenges.
Jun-Ying Wang, Meng-Ping Chen, Jinxing Jiang, Yike Wan, Xin Li, Min-Yue Zhang, F. Xiao, L. Zhong, Hua Zhong, Zhao-yu Qin, Jian Hou   +10 more
semanticscholar   +1 more source

UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats

Infection and Drug Resistance, 2020
Shuang-long Li, Yi Zhang, Qian-shi Cheng, Jun-zhe Xin, Ze-qin Dong, Xiang-jun Qiu School of Basic Medicine, Henan University of Science and Technology, Luoyang 471023, People’s Republic of ChinaCorrespondence: Xiang-jun QiuSchool of Basic Medicine,
Li S, Zhang Y, Cheng Q, Xin J, Dong Z, Qiu X   +5 more
doaj  

Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma

Annals of Hematology
Purpose: T-cell lymphoblastic lymphoma (T-LBL) has a poor response to traditional chemotherapy regimens, and is prone to relapse after treatment. Effective drugs are lacking for relapsed and refractory (RR) T-LBL patients, highlighting the need for novel
Miaomiao Meng, Xiao-Yan Feng, Yue Zhang, Yu-Yang Gao, Li-Juan Han, Zhao-Ming Li, Xu-Dong Zhang, Ming-Zhi Zhang   +7 more
semanticscholar   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source